Work

Abstract P1-03-02: CYP2D6 intermediate metabolizers includes patient groups with distinct metabolic activity

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs14-p1-03-02

Authors: Daniel L Hertz, Anna C Snavely, Howard L McLeod, Christine M Walko, Joseph G Ibrahim, Steven Anderson, Karen E Weck, Peter Rubin, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R Carrizosa, Steven Corso, Gary Schwartz, Jeffrey M Peppercorn, James P Evans, Zeruesenay Desta, David A Flockhart, Lisa A Carey, William J Irvin

Institutions: University of Michigan, Moffitt Cancer Center, LabCorp (United States), Hematology Oncology Associates, East Carolina University, Palmetto Hematology Oncology, Duke Cancer Institute, Indiana University, Bon Secours Health System

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1615414751

Cites:

Cited by: 1

Related to: 10